Is ONTX a good stock to buy now?
The consensus among 1 Wall Street analyst covering (NASDAQ: ONTX) stock is to Strong Buy ONTX stock.
How high will ONTX stock go?
Stock Price Forecast The 14 analysts offering 12-month price forecasts for BioNTech SE have a median target of 221.15, with a high estimate of 349.25 and a low estimate of 160.25.
Why did ONTX stock drop so much?
Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate.
Will ONTX reverse split?
Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, May 21, 2021.
Should I invest in BioNTech?
BioNTech has had an excellent 2021. 2022 and beyond will most likely not be this good, however. The company is very reliant on its COVID vax business today, but BNTX has some attractive pipeline candidates. For risk-hungry investors, BNTX might have value today.
Is BioNTech stock overvalued?
Andersen has long seen both Moderna and BioNTech shares as heavily overvalued. The recent losses bring the two firms closer to what she sees as fairly valued. However, both firms still trade at a premium to her fair value estimates.
Will ONTX go up?
Onconova Therapeutics Inc (NASDAQ:ONTX) The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +746.15% increase from the last price of 1.30.
What does onconova therapeutics do?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
How much is Onconova Therapeutics stock worth in 2021?
The Onconova Therapeutics stock price gained 2.14% on the last trading day (Friday, 9th Jul 2021), rising from $6.07 to $6.20. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 4.33% from a day low at $6.00 to a day high of $6.26. The price has fallen in 7 of the last 10 days and is down by -16.55% for this period. Volume fell on the last day by -90 thousand shares and in total, 234 thousand shares were bought and sold for approximately $1.45 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Does Onconova Therapeutics gain volume?
Onconova Therapeutics gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
When is Onconova 2021?
(NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 . The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are
How much cash is in the first quarter of 2021?
First Quarter Financial Results Cash and cash equivalents as of March 31, 2021 were $48.0 million, compared with $19.0 million as of December 31, 2020. The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations for more than 18 months.
Is Onconova a multi-kinase inhibitor?
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, ...
